Published in Vaccine on June 15, 2007
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (2009) 4.18
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ (2008) 3.08
Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med (2008) 3.02
Modeling cervical cancer prevention in developed countries. Vaccine (2008) 1.61
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer (2011) 1.53
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer (2007) 1.45
Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer (2008) 1.30
Emerging vaccine informatics. J Biomed Biotechnol (2011) 1.12
Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med (2011) 1.09
Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine (2010) 1.07
An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol (2014) 0.99
A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study. PLoS One (2013) 0.97
HPV and cervical cancer: screening or vaccination? Br J Cancer (2008) 0.97
Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J Cancer (2015) 0.95
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health (2009) 0.94
Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate. J Adolesc Health (2010) 0.89
Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis (2011) 0.88
Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model. BMC Infect Dis (2012) 0.87
Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women. Int J STD AIDS (2010) 0.86
How protective is cervical cancer screening against cervical cancer mortality in developing countries? The Colombian case. BMC Health Serv Res (2010) 0.83
Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol (2011) 0.81
Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model. Springerplus (2013) 0.80
Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations. Pharmacoeconomics (2017) 0.79
Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries. PLoS One (2016) 0.77
Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. Eur J Pediatr (2009) 0.77
New technologies for cervical cancer screening. Best Pract Res Clin Obstet Gynaecol (2011) 0.77
Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil. Clinics (Sao Paulo) (2015) 0.77
Modeling optimal cervical cancer prevention strategies in Nigeria. BMC Cancer (2014) 0.76
Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One (2013) 0.76
Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC Health Serv Res (2017) 0.75
Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil. Hum Vaccin Immunother (2014) 0.75
Cost-Effectiveness of Dengue Vaccination Programs in Brazil. Am J Trop Med Hyg (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
International network of cancer genome projects. Nature (2010) 20.35
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med (2005) 6.72
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis (2010) 4.42
Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr (2003) 4.35
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst (2012) 3.87
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med (2013) 3.83
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer (2012) 3.35
The epidemiology of genital human papillomavirus infection. Vaccine (2006) 3.28
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.25
Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis (2011) 3.16
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine (2006) 2.95
Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol (2007) 2.90
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol (2007) 2.49
Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2006) 2.39
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol (2004) 2.36
Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med (2007) 2.35
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine (2006) 2.25
Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00
Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control (2003) 2.00
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst (2012) 1.99
Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr Blood Cancer (2008) 1.98
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis (2011) 1.95
Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis (2009) 1.89
Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med (2011) 1.89
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst (2003) 1.84
The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers (2007) 1.83
Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ (2013) 1.81
Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer (2003) 1.78
Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77
Risk factors of invasive cervical cancer in Mali. Int J Epidemiol (2002) 1.74
Cost-effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States. Ann Emerg Med (2013) 1.74
Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis (2008) 1.72
Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine (2006) 1.71
Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer (2012) 1.69
Management of low-grade cervical lesions in young women. CMAJ (2005) 1.69
Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer (2010) 1.65
Assessing the gain in diagnostic performance when combining two diagnostic tests. Stat Med (2002) 1.65
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
What is the most cost-effective population-based cancer screening program for Chinese women? J Clin Oncol (2007) 1.62
FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J (2010) 1.60
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst (2006) 1.58
Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine (2012) 1.58
Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health (2007) 1.53
Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol (2006) 1.53
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer (2011) 1.53
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res (2010) 1.50
NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. Leuk Res (2011) 1.44
Diagnosis delays in childhood cancer: a review. Cancer (2007) 1.44
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. Ann Intern Med (2015) 1.39
Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis (2012) 1.38
Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.34
Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol (2007) 1.34
Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population. J Clin Microbiol (2004) 1.34
Chlamydia trachomatis infection in female partners of circumcised and uncircumcised adult men. Am J Epidemiol (2005) 1.33
Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev (2005) 1.32
Making prospective registration of observational research a reality. Sci Transl Med (2014) 1.31
Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2003) 1.31
FOXO1 transrepresses peroxisome proliferator-activated receptor gamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes. J Biol Chem (2009) 1.29
Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine (2006) 1.27
p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev (2004) 1.26
Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction (2004) 1.26
Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer (2012) 1.23
A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine (2012) 1.22
Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer (2006) 1.22
Human papillomavirus infections among couples in new sexual relationships. Epidemiology (2010) 1.20
Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine (2006) 1.20
Human papillomavirus in cervical cancer. Curr Oncol Rep (2002) 1.19
The fractalkine/CX3CR1 system regulates β cell function and insulin secretion. Cell (2013) 1.16
Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev (2010) 1.16
Human Papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain. BMC Infect Dis (2009) 1.15
Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis (2011) 1.15
Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med (2008) 1.15
Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma--a multicentre European case-control study. Int J Epidemiol (2008) 1.15
Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiol Biomarkers Prev (2008) 1.14
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One (2013) 1.14
Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res (2008) 1.13
Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis (2008) 1.12
Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine (2012) 1.12